Cargando...
Profile of nintedanib in the treatment of solid tumors: the evidence to date
Angiogenesis is an essential process for tumor growth and metastasis, and remains a promising therapeutic target process in cancer treatment for several cancer types. Bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF), was the first antiangiogenic agent approve...
Guardado en:
| Publicado en: | Onco Targets Ther |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4677757/ https://ncbi.nlm.nih.gov/pubmed/26677336 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S78805 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|